Brolucizumab, a novel anti-VEGF agent for wet macular degeneration, has reported promising results in phase II clinical trials, and Phase III trials are underway. What is interesting is that many patients appear to be maintained on one of these injections every 12 weeks. More data will doubtless become available from larger studies in due course.
http://www.eurotimes.org/node/2225